CO5550458A2 - Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) - Google Patents
Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)Info
- Publication number
- CO5550458A2 CO5550458A2 CO05025189A CO05025189A CO5550458A2 CO 5550458 A2 CO5550458 A2 CO 5550458A2 CO 05025189 A CO05025189 A CO 05025189A CO 05025189 A CO05025189 A CO 05025189A CO 5550458 A2 CO5550458 A2 CO 5550458A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- amino
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto de fórmula (A) o una sal, profármaco, hidrato, tautómero o solvato farmacéuticamente aceptable del mismo en el que:X es O o S;R1 es un anillo saturado, insaturado o aromático C3-C20, mono-, bi- o policíclico que contiene, opcionalmente, al menos un heteroátomo seleccionado del grupo constituido por N, O y S; R1 puede estar opcionalmente sustituido independientemente además con al menos un resto seleccionado independientemente del grupo constituido por: carbonilo, halo, haloalquilo(C1-C6), perhaloalquilo(C1-C6), perhaloalcoxi(C1-C6), alquilo(C1-C6), alquenilo(C2-C6), alquinilo (C2-C6), hidroxi, oxo, mercapto, alquil(C1-C6)tio, alcoxi(C1-C6), arilo(C5-C10) o heteroarilo(C5-C10), aril(C5-C10)oxi o heteroaril(C5-C10)oxi, aril(C5-C10)alquilo(C1-C6) o heteroaril(C5-C10)alquilo(C1-C6), aril(C5-C10)alcoxi(C1-C6) o heteroaril(C5-C10)alcoxi(C1-C6), HO-(C=O)-, éster, amido, éter, amino, aminoalquilo(C1-C6), alquil(C1-C6)aminoalquilo(C1-C6), dialquil(C1-C6)aminoalquilo(C1-C6), heterociclil(C5-C10)alquilo(C1-C6), alquil(C1-C6)- y dialquil(C1-C6)amino, ciano, nitro, carbamoílo, alquil(C1-C6)carbonilo, alcoxi(C1-C6)carbonilo, alquil(C1-C6)aminocarbonilo, dialquil(C1-C6)aminocarbonilo, aril(C5-C10)carbonilo, aril(C5-C10)oxicarbonilo, alquil(C1-C6)sulfonilo y aril( C5-C10)sulfonilo;cada R3 se selecciona independientemente del grupo constituido por hidrógeno, halo, haloalquilo(C1-C6), alquilo(C1-C6), alquenilo(C2-C6), alquinilo(C2-C6), perhaloalquilo(C1-C6), fenilo, heteroarilo(C5-C10), heterociclilo(C5-C10), cicloalquil(C3-C10), hidroxi, alcoxi(C1-C6), perhaloalcoxi(C1-C6), fenoxi, heteroaril(C5-C10)-O-, heterociclil(C5-C10)-O-, cicloalquil(C3-C10)-O-, alquil(C1-C6)-S-, alquil(C1-C6)-SO2-, alquil(C1-C6)-NH-SO2-, O2N-, NC-, amino, Ph(CH2)1-6HN-, alquil(C1-C6)-HN-, alquil(C1-C6)amino, [alquil(C1-C6)]2-amino, alquil(C1-C6)-SO2-NH-, amino(C=O)-, aminoO2S-, alquil(C1-C6)-(C=O)-NH-, alquil(C1-C6)-(C=O)-[(alquil(C1-C6))-N]-, fenil-(C=O)-NH-, fenil-(C=O)-[alquil(C1-C6)-N]-, alquil(C1-C6)-(C=O)-, fenil-(C=O)-, heteroaril(C5-C10)-(C=O)-, heterociclil(C5-C10)-(C=O)-, cicloalquil(C3 -C10)-(C=O)-, HO-(C=O)-, alquil(C1-C6)-O-(C=O)-, H2N(C=O)-, alquil(C1-C6)-NH-(C=O)-, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41213102P | 2002-09-18 | 2002-09-18 | |
| US48458003P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5550458A2 true CO5550458A2 (es) | 2005-08-31 |
Family
ID=32033584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05025189A CO5550458A2 (es) | 2002-09-18 | 2005-03-18 | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7030125B2 (es) |
| EP (1) | EP1542995A1 (es) |
| JP (1) | JP2006506443A (es) |
| KR (1) | KR20050057441A (es) |
| CN (1) | CN1681809A (es) |
| AP (1) | AP2005003262A0 (es) |
| AR (1) | AR041275A1 (es) |
| AU (1) | AU2003263431A1 (es) |
| BR (1) | BR0314286A (es) |
| CA (1) | CA2499332A1 (es) |
| CO (1) | CO5550458A2 (es) |
| EA (1) | EA200500286A1 (es) |
| EC (1) | ECSP055685A (es) |
| HR (1) | HRP20050246A2 (es) |
| IS (1) | IS7695A (es) |
| MA (1) | MA27444A1 (es) |
| MX (1) | MXPA05002378A (es) |
| NO (1) | NO20051852L (es) |
| OA (1) | OA12925A (es) |
| PA (1) | PA8583101A1 (es) |
| PE (1) | PE20050076A1 (es) |
| PL (1) | PL375973A1 (es) |
| TW (1) | TW200410954A (es) |
| UY (1) | UY27983A1 (es) |
| WO (1) | WO2004026865A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003263404A1 (en) * | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| OA12926A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors. |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| AR051202A1 (es) | 2004-09-20 | 2006-12-27 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| BRPI0515478A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase |
| AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| JP5123671B2 (ja) | 2005-02-17 | 2013-01-23 | シンタ ファーマシューティカルズ コーポレーション | 増殖性疾患の治療のための化合物 |
| CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
| AU2006325706B2 (en) * | 2005-12-16 | 2012-03-29 | Novartis Ag | Control of intraocular pressure using ALK5 modulation agents |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN105358677B (zh) | 2013-03-14 | 2018-06-15 | 布里格海姆妇女医院公司 | 用于上皮干细胞扩增和培养的组合物和方法 |
| HUE050761T2 (hu) | 2014-01-01 | 2021-01-28 | Medivation Tech Llc | Vegyületek és alkalmazási eljárások |
| WO2016037016A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| EP4049665A1 (en) | 2016-03-15 | 2022-08-31 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| EP3768267A4 (en) | 2018-03-20 | 2022-04-20 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| AU2019419414A1 (en) | 2018-12-31 | 2023-04-06 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5095272A (es) * | 1973-12-24 | 1975-07-29 | ||
| JP2002502379A (ja) | 1997-05-22 | 2002-01-22 | ジー．ディー．サール アンド カンパニー | ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| EP1019394A1 (en) | 1997-05-22 | 2000-07-19 | G.D. Searle & Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
| GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| EP1363904A1 (en) * | 2001-02-02 | 2003-11-26 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US20050245520A1 (en) | 2002-07-31 | 2005-11-03 | Nerina Dodic | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors |
-
2003
- 2003-09-12 CA CA002499332A patent/CA2499332A1/en not_active Abandoned
- 2003-09-12 JP JP2004568905A patent/JP2006506443A/ja not_active Withdrawn
- 2003-09-12 PL PL03375973A patent/PL375973A1/xx not_active Application Discontinuation
- 2003-09-12 EA EA200500286A patent/EA200500286A1/ru unknown
- 2003-09-12 AP AP2005003262A patent/AP2005003262A0/xx unknown
- 2003-09-12 OA OA1200500074A patent/OA12925A/en unknown
- 2003-09-12 CN CNA038222043A patent/CN1681809A/zh active Pending
- 2003-09-12 WO PCT/IB2003/004005 patent/WO2004026865A1/en active Application Filing
- 2003-09-12 EP EP03797466A patent/EP1542995A1/en not_active Withdrawn
- 2003-09-12 BR BR0314286-8A patent/BR0314286A/pt not_active IP Right Cessation
- 2003-09-12 MX MXPA05002378A patent/MXPA05002378A/es active IP Right Grant
- 2003-09-12 KR KR1020057004662A patent/KR20050057441A/ko not_active Application Discontinuation
- 2003-09-12 AU AU2003263431A patent/AU2003263431A1/en not_active Abandoned
- 2003-09-15 TW TW092125380A patent/TW200410954A/zh unknown
- 2003-09-16 UY UY27983A patent/UY27983A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103359A patent/AR041275A1/es unknown
- 2003-09-17 PE PE2003000951A patent/PE20050076A1/es not_active Application Discontinuation
- 2003-09-17 PA PA20038583101A patent/PA8583101A1/es unknown
- 2003-09-17 US US10/667,167 patent/US7030125B2/en not_active Expired - Fee Related
-
2005
- 2005-02-14 IS IS7695A patent/IS7695A/is unknown
- 2005-03-16 HR HR20050246A patent/HRP20050246A2/hr not_active Application Discontinuation
- 2005-03-17 EC EC2005005685A patent/ECSP055685A/es unknown
- 2005-03-18 CO CO05025189A patent/CO5550458A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28158A patent/MA27444A1/fr unknown
- 2005-04-15 NO NO20051852A patent/NO20051852L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL375973A1 (en) | 2005-12-12 |
| CA2499332A1 (en) | 2004-04-01 |
| UY27983A1 (es) | 2004-04-30 |
| US20040116473A1 (en) | 2004-06-17 |
| AP2005003262A0 (en) | 2005-03-31 |
| EA200500286A1 (ru) | 2005-08-25 |
| MA27444A1 (fr) | 2005-07-01 |
| NO20051852L (no) | 2005-06-16 |
| PA8583101A1 (es) | 2004-04-23 |
| AR041275A1 (es) | 2005-05-11 |
| MXPA05002378A (es) | 2005-05-23 |
| TW200410954A (en) | 2004-07-01 |
| EP1542995A1 (en) | 2005-06-22 |
| BR0314286A (pt) | 2005-08-02 |
| AU2003263431A1 (en) | 2004-04-08 |
| IS7695A (is) | 2005-02-14 |
| JP2006506443A (ja) | 2006-02-23 |
| WO2004026865A1 (en) | 2004-04-01 |
| HRP20050246A2 (en) | 2005-10-31 |
| OA12925A (en) | 2006-10-13 |
| KR20050057441A (ko) | 2005-06-16 |
| CN1681809A (zh) | 2005-10-12 |
| ECSP055685A (es) | 2005-05-30 |
| US7030125B2 (en) | 2006-04-18 |
| PE20050076A1 (es) | 2005-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5550458A2 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
| CO5550473A2 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformadors (tgf) | |
| CO5550456A2 (es) | Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO5550453A2 (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO5540390A2 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| JO2668B1 (en) | Isoczazolins for controlling invertebrate insects | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| AR043449A1 (es) | Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| CO5611113A2 (es) | Tripeptidos que poseen un eter de hidroxiprolina de una quinolina sustituida para la inhibicion de ns3 (hepatitis c) | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| AR048361A1 (es) | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos | |
| DOP2002000333A (es) | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
| PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| AR066972A1 (es) | Derivados azapeptidicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |